Debra Stokan
Psychiatry · Katy, TXNPI 1316059595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 576 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,626, 4.1 times the $644 reported in 2019. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$912
- Supernus Pharmaceuticals, Inc.$860
- Lundbeck LLC$751
- AbbVie$724
- Takeda Pharmaceuticals U.S.A., Inc.$693
- Otsuka America Pharmaceutical, Inc.$677
- plus $6K from 26 others
What the payments were for
- Food & beverage$10,16499%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 43 | $912 |
| Supernus Pharmaceuticals, Inc. | 50 | $860 |
| Lundbeck LLC | 46 | $751 |
| AbbVie | 42 | $724 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $693 |
| Otsuka America Pharmaceutical, Inc. | 36 | $677 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $627 |
| Tris Pharma Inc | 33 | $623 |
| Sunovion Pharmaceuticals Inc. | 44 | $618 |
| Axsome Therapeutics, Inc. | 24 | $542 |
| Noven Therapeutics, LLC | 35 | $483 |
| Ironshore Pharmaceuticals Inc. | 24 | $441 |
| Neos Therapeutics, LP | 30 | $422 |
| Alkermes, Inc. | 16 | $321 |
| Bausch Health US, LLC | 17 | $297 |
| Johnson & Johnson | 13 | $296 |
| Idorsia Pharmaceuticals US Inc | 15 | $273 |
| Vanda Pharmaceuticals Inc. | 10 | $192 |
| Vertical Pharmaceuticals, LLC | 5 | $86 |
| Adlon Therapeutics L.p. | 4 | $70 |
| TMS Neurohealth Centers Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Shire North American Group Inc | 2 | $32 |
| Rhodes Pharmaceuticals L.p. | 2 | $30 |
| Harmony Biosciences LLC | 1 | $27 |
| Sage Therapeutics, LLC | 1 | $26 |
| Tempus AI, Inc | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$138
How this compares
$10,221 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ConcertaMethylphenidate Hcl | 12 | $9,660 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $6,026 |
| Lisdexamfetamine Dimesylate | 19 | $4,615 |
| Dyanavel XrAmphetamine | 13 | $3,423 |
| Aripiprazole | 21 | $3,109 |
| Bupropion XlBupropion Hcl | 60 | $2,446 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,197 |
| Duloxetine Hcl | 54 | $880 |
| Methylphenidate Hcl | 26 | $831 |
| Vilazodone Hcl | 11 | $818 |
| Sertraline Hcl | 51 | $752 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $730 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $718 |
| Quetiapine Fumarate | 21 | $713 |
| Mirtazapine | 24 | $664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonConcerta | $296 | $9,66012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $693 | $6,02615 claims |
| Tris Pharma IncDyanavel Xr | $623 | $3,42313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Katy
- Vikram MehraKaty$1.2M
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.